Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics aimed at treating complement-mediated neurodegenerative and autoimmune diseases. The company's unique scientific approach targets C1q, the initiating molecule of the classical complement pathway, to halt the inflammatory cascade before it starts, providing significant potential benefits across a range of diseases affecting the body, brain, and eye.
Annexon’s primary product candidates include:
- ANX005: A monoclonal antibody designed to block C1q, currently in pivotal Phase 3 trials for Guillain-Barré Syndrome (GBS) and showing promising results in reducing muscle strength loss and nerve damage.
- ANX007: An antigen-binding fragment aimed at treating geographic atrophy (GA) in the eye, demonstrating notable protection against vision loss and retinal damage in Phase 2 trials.
- ANX1502: An oral small molecule inhibitor targeting autoimmune diseases, expected to generate proof-of-concept data in the second half of 2024.
In recent developments, Annexon announced positive top-line results from their Phase 3 trial of ANX005 in GBS, showing significant improvements in clinical outcomes and muscle strength. This trial marks a major milestone as ANX005 could become the first targeted treatment for GBS in the U.S. The company also showcased ANX007's potential in preserving retinal structures and vision in GA patients, with Phase 3 trials set to commence in 2024.
Financially, Annexon maintains a robust balance sheet with approximately $260 million in cash and equivalents, providing a runway into mid-2026. The company recently completed a public offering to raise additional capital, further strengthening its financial position to advance its clinical programs.
Annexon continues to advance its pipeline rigorously, with multiple upcoming milestones that have the potential to generate substantial value for patients and shareholders alike.
Annexon, Inc. (Nasdaq: ANNX) announced its progress in clinical trials and financial results for 2022, highlighting its commitment to developing complement therapies. The company reported cash and equivalents of $242.7 million as of December 31, 2022, providing a runway into 2025. Significant milestones include anticipated mid-2023 data from the Phase 2 trial of ANX007 for geographic atrophy and ongoing trials for ANX1502, focusing on autoimmune conditions. R&D expenses were $112.5 million for 2022, with a net loss of $141.9 million. The company remains optimistic about its pipeline and future developments.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), is set to participate in the 43rd Annual Cowen Healthcare Conference on March 6, 2023, at 1:30 p.m. ET in Boston. CEO Douglas Love will engage in a fireside chat during the event. Interested parties can access the live webcast on Annexon's Investors page, with a replay available for 30 days post-event. Annexon focuses on creating innovative complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders, and is advancing a diversified pipeline with clinical data expected in 2023 and beyond.
Annexon, Inc. (Nasdaq: ANNX) announced on February 16, 2023, the granting of equity inducement awards to four new non-executive employees. This initiative aligns with the 2022 Employment Inducement Award Plan and complies with Nasdaq Listing Rule 5635(c)(4). A total of 182,000 stock options were issued, each priced at $5.90, the closing price on the grant date. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary of employment. Annexon focuses on developing innovative complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with multiple clinical trials expected in 2023.
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, has granted a significant equity inducement award to its chief scientific officer, Dean “Rick” Artis, Ph.D. The award, effective January 15, 2023, includes an option to purchase 210,000 shares at an exercise price of $6.84, the closing price on January 13, 2023. This option has a ten-year term and will vest over four years. Annexon is focused on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with multiple clinical trials underway and anticipated readouts throughout 2023 and beyond.
Annexon, Inc. (Nasdaq: ANNX) announced significant advancements in its clinical trials for novel complement therapies. The company aims to achieve critical milestones in 2023, including the expanded enrollment of its Phase 3 trial for ANX005 in Guillain-Barré syndrome and the initiation of a pivotal trial for Huntington’s disease. Annexon plans to present updates at the J.P. Morgan Healthcare Conference on January 11, 2023. With $269.5 million in cash, the company has a robust operating runway extending into 2025, positioning itself strongly for continued development in the autoimmune and neurodegenerative disease sectors.
Annexon, Inc. (Nasdaq: ANNX) announced the appointment of Dr. Dean “Rick” Artis as chief scientific officer, succeeding Dr. Larry C. Mattheakis. Dr. Artis returns after serving as CSO at Octant Bio, having previously led key developments at Annexon. He will oversee all research efforts, focusing on enhancing the company's pipeline of classical complement inhibitors for autoimmune and neurodegenerative diseases. Annexon's pipeline is expected to yield significant clinical data throughout 2023, indicating a potential transformational period for the company.
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that its CEO, Douglas Love, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT in San Francisco. The presentation will be available via live webcast on the Annexon website, and a replay will be accessible for 30 days after the event.
Annexon focuses on developing novel complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders, with several clinical trials expected to yield results throughout 2023.
Annexon, Inc. (Nasdaq: ANNX) announced the grant of an equity inducement award to a new non-executive employee on November 16, 2022, under its 2022 Employment Inducement Award Plan. The award consists of an option to purchase 5,000 shares at an exercise price of $5.77 per share. The option vests over four years, with 25% vesting after the first year and monthly thereafter. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with clinical readouts expected throughout 2023 and beyond.
Annexon, a clinical-stage biopharma, reported Q3 2022 results with a net loss of $35.1 million ($0.51 per share), an improvement from $35.6 million ($0.93 per share) a year earlier. Cash reserves are $269.5 million, sufficient to fund operations into H2 2025. The company is advancing trials for its complement-targeted therapies, including late-stage studies for ANX005 in Guillain-Barré Syndrome and Huntington’s disease. Upcoming presentations at scientific conferences will showcase its novel approaches and preclinical progress on ANX007 for geographic atrophy.
Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, approved on October 17, 2022, involve options to purchase 87,400 shares of common stock, with an exercise price of $5.63 per share, reflecting the closing stock price on the grant date. The options have a ten-year term and vest over four years. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
What does Annexon, Inc. specialize in?
What are Annexon's main product candidates?
What recent achievements has Annexon announced?
What is the financial condition of Annexon?
When are the next key milestones expected for Annexon’s pipeline?
What is the scientific approach of Annexon?
What is the potential impact of ANX007 on GA patients?
How does ANX005 work in treating GBS?
What regulatory designations has ANX005 received?
Where can I find more information about Annexon?
